An interventional study of Gabapentin and Carbamazepine in Guillain-Barré Syndrome and Neuropathic Pain, sponsored by Lahore General Hospital. Completed at 1 site in Pakistan. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Lahore General Hospital · Not applicable, Interventional, and Treatment
This randomized controlled trial compared gabapentin with carbamazepine for the treatment of nerve-related pain in patients with Guillain-Barré syndrome who received plasma exchange. The study tested the hypothesis that pain scores after seven days of treatment differed between the two groups.
The study was conducted at Medical Unit III, Lahore General Hospital, Lahore, and included 60 patients of either sex aged 16-65 years. Patients were randomly assigned by a lottery method to two equal groups of 30 patients each. One group received gabapentin 300 mg three times daily, while the other received carbamazepine 100 mg three times daily. Both treatments were administered after plasma exchange, and patients were followed for seven days.
Pain severity was assessed using a numeric rating scale before treatment and after seven days. Mean pain scores after treatment were compared between the groups to assess their relative effectiveness. Age, sex, duration of Guillain-Barré syndrome, smoking, alcohol use, diabetes, and hypertension were recorded, and comparisons were also performed within subgroups defined by these characteristics.
96 studies on the registry are indexed under Guillain-Barre Syndrome; 28 are open to participants now.
This study's enrollment of 60 is above the median of 50 across 43 interventional studies indexed under Guillain-Barre Syndrome.
Browse Guillain-Barre Syndrome studies →Lahore General Hospital is the lead sponsor of 32 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients received gabapentin 300 mg three times daily for seven days after plasma exchange for Guillain-Barré syndrome.
Drug: Gabapentin
Patients received carbamazepine 100 mg three times daily after plasma exchange
Drug: Carbamazepine
Gabapentin 300 mg was administered three times daily for seven days to treat neuropathic pain.
Carbamazepine 100 mg was administered three times daily to treat neuropathic pain, with pain assessment after seven days.
Mean neuropathic pain score
Neuropathic pain severity was assessed using a numeric rating scale at baseline and after seven days of treatment. Mean pain scores at day seven were compared between patients receiving gabapentin and those receiving carbamazepine. Lower scores indicated less severe pain.
Time frame: Baseline and 7 day after initiation of treatment.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Lahore General Hospital